FDA On Celebrex: Use Low Dose, If At All

FDA is advising physicians to consider alternative therapies and lowest effective dose. During a teleconference, FDA’s Crawford says Celebrex and COX-2s may be appropriate for patients who need favorable GI profile compared to older NSAIDs, despite celecoxib product warning on NSAID GI toxicity.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet